Tecarfarin sodium is under clinical development by Cadrenal Therapeutics and currently in Phase I for Thrombosis. According to GlobalData, Phase I drugs for Thrombosis have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tecarfarin sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tecarfarin sodium overview

Tecarfarin is under development for the treatment of antiphospholipid syndrome, systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation and thrombosis. The drug candidate is administered through oral route. It is a small molecule. It is designed to have the same therapeutic benefits as the drug warfarin. Tecarfarin targets Vitamin K epoxide reductase (VKOR) enzyme. The drug candidate is designed based on retrometabolic drug design technology. 

Cadrenal Therapeutics overview

Cadrenal Therapeutics is a biopharmaceutical company developing a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin. Cadrenal Therapeutics is headquartered in Ponte Vedra, Florida, the US.

For a complete picture of Tecarfarin sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.